LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
Lifevantage Corp Chief Financial Officer Aure Carl reported a routine tax-related share transfer. On April 1, 2026, he disposed of 1,527 shares of common stock at an indicated value of $4.20 per share to cover tax obligations by delivering shares.
After this tax-withholding disposition, Carl directly holds 156,915 shares of Lifevantage common stock. Because the transaction was for tax payment rather than an open-market sale, it reflects compensation-related administration rather than an active decision to buy or sell shares in the market.
Lifevantage Corp chief sales officer Kristen Cunningham reported a small share disposition related to tax withholding. On a compensation-related transaction, 1,928 shares of common stock were withheld at $4.20 per share to cover tax obligations.
After this event, she continues to directly hold 133,134 shares of Lifevantage common stock.
The Capital Management Corporation reported beneficial ownership of 2,441,919 shares of LifeVantage Corporation, representing 19.1% of the company's common stock as of 03/31/2026. The filing is an Amendment No. 3 to a Schedule 13G/A and is signed by Pamela C. Simms as Compliance Officer.
The filing shows sole voting power over 2,406,719 shares and sole dispositive power over 2,441,919 shares. The filing lists The Capital Management Corporation as the reporting entity and provides its Virginia principal business address.
Lifevantage Corp director Lewis Darwin reported an open-market purchase of common stock. On this transaction date, he bought 1,055 shares at $5.23 per share, increasing his direct holdings to 136,563 shares. This filing shows a modest increase in his personal investment in the company.
LifeVantage Corporation is registering up to $75.0 million of securities on a shelf registration.
The shelf permits the company to offer common stock, preferred stock, debt securities, warrants and units from time to time, in one or more series, with specific terms to be provided in prospectus supplements. The prospectus caps aggregate sales under the shelf at $75.0 million and states offerings may be made through underwriters, dealers, agents or directly.
The company’s common stock trades on the Nasdaq Capital Market under the symbol LFVN; the prospectus cites a last reported sale price of $4.91 per share on March 4, 2026. Shares issued and outstanding were 12,804,772 as of March 4, 2026, and the prospectus reports an aggregate market value of common stock held by non‑affiliates of $65,580,155 based on 12,793,359 outstanding shares as of February 26, 2026.
Lifevantage Corp director Dayton Judd reported open-market purchases of the company’s common stock. He bought 10,500 shares on March 2, 2026 at $4.53, 18,097 shares on February 27, 2026 at $4.63, and 4,600 shares on February 26, 2026 at $4.58, totaling 33,197 shares.
After these transactions, Judd directly owns 80,359 shares. The filing also shows 749,325 shares held indirectly through Sudbury Capital Fund, LP, an investment entity with which he is associated.
LifeVantage director Darwin Lewis bought 3,955 shares of company common stock in an open‑market transaction at a weighted average price of $5.2216 per share. After this purchase on February 9, 2026, he directly owns 135,508 LifeVantage shares.
LifeVantage Corporation filed a current report describing two key updates. The company issued a press release announcing financial results for the three and six months ended December 31, 2025, which is furnished as Exhibit 99.1. The report also discloses that President and Chief Executive Officer Steven R. Fife has decided to retire and will resign as CEO and from the board, with his resignation expected to be effective in April 2026. The company states that Mr. Fife’s decision to retire is not due to any disagreement regarding operations, financial policies, or practices, and additional details are provided in a second press release furnished as Exhibit 99.2.
LifeVantage Corporation reported weaker results for the quarter ended December 31, 2025 as revenue fell to $48.9 million from $67.8 million a year earlier, mainly from lower sales of its MindBody GLP-1 System™. Net income declined to $0.3 million from $2.6 million, with gross margin pressured by about $2.4 million of inventory obsolescence tied to this product line.
For the first six months, revenue was $96.5 million versus $115.0 million, and net income was $2.4 million versus $4.4 million. Active accounts fell 21.2% year over year to 115,000, reflecting fewer independent consultants and customers. The company completed a $4.2 million acquisition of LoveBiome assets, adding a new gut-health product line, and ended the period with $10.2 million in cash and no borrowings on its $5.0 million credit facility.